Dysautonomia in anti-Hu paraneoplastic neurological syndromes

被引:1
|
作者
Villagran-Garcia, Macarena [1 ,2 ]
Farina, Antonio [1 ,2 ,3 ]
Arzalluz-Luque, Joaquin [1 ,4 ]
Campetella, Lucia [1 ]
Muniz-Castrillo, Sergio [1 ,5 ]
Benaiteau, Marie [1 ]
Peter, Elise [1 ,2 ]
Dumez, Pauline [1 ,2 ]
Wucher, Valentin [1 ,2 ]
Dhairi, Maroua [1 ]
Picard, Geraldine [1 ]
Rafiq, Marie [6 ]
Psimaras, Dimitri [7 ,8 ]
Rogemond, Veronique [1 ,2 ]
Joubert, Bastien [1 ,2 ]
Honnorat, Jerome [1 ,2 ]
机构
[1] Hosp Civils Lyon, Hop Neurol, French Reference Ctr Paraneoplast Neurol Syndromes, 59 Bd Pinel, F-69677 Bron, France
[2] Univ Claude Bernard Lyon 1, CNRS UMR 5284, UCBL,U1314, INSERM,MeLiS, F-69008 Lyon, France
[3] Univ Florence, Dept Neurosci Psychol Pharmacol & Child Hlth, I-50139 Florence, Italy
[4] Hosp Univ Virgen Macarena, Dept Neurol, Seville 41009, Spain
[5] Stanford Univ, Ctr Sleep Sci & Med, Palo Alto, CA 94304 USA
[6] Univ Hosp Toulouse, Dept Neurol, F-31300 Toulouse, France
[7] Hosp Grp Pitie Salpetriere, AP HP, Neurol Dept Mazarin 2, F-75013 Paris, France
[8] Paris Brain Inst, Inst Cerveau & Moelle Epiniere ICM, Inserm, CNRS, F-75013 Paris, France
关键词
Dysautonomia; Autonomic function; Paraneoplastic autoimmunity; Hu; ANNA-1; POSITIVE PATIENTS; ENCEPHALOMYELITIS; TUMOR;
D O I
10.1007/s00415-024-12278-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and objectives Dysautonomia has been associated with paraneoplastic neurological syndrome (PNS)-related mortality in anti-Hu PNS, but its frequency and spectrum remain ill-defined. We describe anti-Hu patients with dysautonomia, estimate its frequency, and compare them to patients without dysautonomia. Methods Patients with anti-Hu antibodies diagnosed in the study centre (1990-2022) were retrospectively reviewed; those with autonomic signs and symptoms were identified. Results Among 477 anti-Hu patients, 126 (26%) had dysautonomia (the only PNS manifestation in 7/126, 6%); gastrointestinal (82/126, 65%), cardiovascular (64/126, 51%), urogenital (24/126, 19%), pupillomotor/secretomotor (each, 11/126, 9%), and central hypoventilation (10/126, 8%). Patients with isolated CNS involvement less frequently had gastrointestinal dysautonomia than those with peripheral (alone or combined with CNS) involvement (7/23, 30% vs. 31/44, 70% vs. 37/52, 71%; P = 0.002); while more frequently central hypoventilation (7/23, 30% vs. 1/44, 2.3% vs. 2/52, 4%; P < 0.001) and/or cardiovascular alterations (18/23, 78% vs. 20/44, 45% vs. 26/52, 50%; P = 0.055). Median [95% CI] overall survival was not significantly different between patients with (37 [17; 91] months) or without dysautonomia (28 [22; 39] months; P = 0.78). Cardiovascular dysautonomia (HR: 1.57, 95% CI [1.05; 2.36]; P = 0.030) and central hypoventilation (HR: 3.51, 95% CI [1.54; 8.01]; P = 0.003) were associated with a higher risk of death, and secretomotor dysautonomia a lower risk (HR: 0.28, 95% CI [0.09; 0.89]; P = 0.032). Patients with cardiovascular dysautonomia dying <= 1 year from clinical onset had severe CNS (21/27, 78%), frequently brainstem (13/27, 48%), involvement. Discussion Anti-Hu PNS dysautonomia is rarely isolated, frequently gastrointestinal, cardiovascular and urogenital. CNS dysfunction, particularly brainstem, associates with lethal cardiovascular alterations and central hypoventilation, while peripheral involvement preferentially associates with gastrointestinal or secretomotor dysautonomia, being the latest more indolent.
引用
收藏
页码:3359 / 3369
页数:11
相关论文
共 50 条
  • [31] Paraneoplastic Anti-HU Syndrome Associated with Uterine Tumor
    Cote-Mantha, Evelyne
    Savard, Martin
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2012, 39 (02) : 254 - 255
  • [32] Analysis of TCR usage in the anti-Hu paraneoplastic syndrome
    Rosenfeld, MR
    Voltz, RD
    Eichen, JG
    Deschamps, T
    Dalmau, JO
    Posner, JB
    NEUROLOGY, 1998, 50 (04) : A384 - A384
  • [33] Opercular myoclonic-anarthric status (OMASE) secondary to anti-Hu paraneoplastic neurological syndrome
    Romero, Cesar
    Quijada, Alonso
    Abudinen, Gabriel
    Cespedes, Catherine
    Aguilera, Ledda
    EPILEPSY & BEHAVIOR REPORTS, 2024, 27
  • [34] Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes
    A. Storstein
    M. Raspotnig
    R. Vitaliani
    B. Giometto
    F. Graus
    W. Grisold
    J. Honnorat
    C. A. Vedeler
    Journal of Neurology, 2016, 263 : 1001 - 1007
  • [35] Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes
    Storstein, A.
    Raspotnig, M.
    Vitaliani, R.
    Giometto, B.
    Graus, F.
    Grisold, W.
    Honnorat, J.
    Vedeler, C. A.
    JOURNAL OF NEUROLOGY, 2016, 263 (05) : 1001 - 1007
  • [36] Treatment of paraneoplastic neurological syndromes (PNS) with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins (IV Ig), cyclophosphamide (CT), and methylprednisolone (MP)
    Fleury, A
    Rene, R
    Keime, F
    Honnorat, J
    Antoine, JC
    Delattre, JY
    Graus, F
    NEUROLOGY, 1997, 48 (03) : 1009 - 1009
  • [37] Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy
    Molinuevo, JL
    Graus, F
    Serrano, C
    Reñe, R
    Guerrero, A
    Illa, I
    ANNALS OF NEUROLOGY, 1998, 44 (06) : 976 - 980
  • [38] Anti-Hu antibody-mediated paraneoplastic cerebellar degeneration
    Vazquez Rico, I.
    Cabra Rodriguez, R.
    Rodriguez Bayona, B.
    Barco Sanchez, A.
    Castano Lopez, M. A.
    Leon-Justel, A.
    CLINICA CHIMICA ACTA, 2019, 493 : S122 - S123
  • [39] Facial pain as first manifestation of anti-Hu paraneoplastic syndrome
    Demarquay, Genevieve
    Didelot, Adrien
    Rogemond, Veronique
    Ryvlin, Philippe
    Gouttard, Michel
    Garassus, Paul
    Mauguiere, Francois
    Honnorat, Jerome
    JOURNAL OF HEADACHE AND PAIN, 2010, 11 (04): : 355 - 357
  • [40] Paraneoplastic Gastro-Intestinal Anti-Hu Syndrome in Neuroblastoma
    Drukker, C. A. M.
    Heij, H. A.
    Wijnaendts, L. C. D.
    Verbeke, J. I. M. L.
    Kaspers, G. J. L.
    PEDIATRIC BLOOD & CANCER, 2009, 52 (03) : 396 - 398